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We present the incidence of hospital-acquired pneumonia (HAP) in Portugal during a 
4-year period (2014-2017). Data were retrieved from the 100 Portuguese Hospital 
diagnosis discharge database for adult patients and included gender, age, chronic 
comorbidities, mortality and hospital length of stay. 
We found 28,632 episodes of HAP, an incidence of 0.95 per 100 admissions. HAP 
patients had both a prolonged hospital length of stay (mean 26.4 days) and high 
mortality (33.6%). Most episodes occurred in patients aged ≥65 years and in males 
(76.1% and 61.7%, respectively). Invasive ventilation was required in 18.8%. 
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Hospital-acquired infections, especially pneumonia (HAP), remain one of the most 
important challenges clinicians face in everyday work [1]. Nevertheless, the 
epidemiology of HAP is uncertain. Epidemiological studies focusing on HAP in non-
ventilated patients suggest that the incidence may be twice as high as that of ventilator 
associated pneumonia [2,3], with similar mortality rate [2] and frequently leading to 
ICU admission [2]. 
There is scarce information regarding both HAP risk and incidence outside the ICU, and 
epidemiological data regarding HAP global incidence is clearly needed. 
In this study we addressed the incidence of HAP at a national level. We studied data 
from four consecutive years (2014-2017) to account for possible seasonal variation. We 
included all hospitals, both community and university, of the Portuguese mainland 
health care system. We aimed to determine the burden of HAP nationally, and to 
identify the sub-groups at higher risk. 
 
Methods.  
The Central Administration of the Health System of the Portuguese Ministry of Health 
records administrative and clinical discharge data for all admissions to the 100 (77 
General) National Health System hospitals in mainland Portugal. The anonymized 
database includes all discharge diagnoses of hospital inpatients, either dead or alive,
codified according to the International Classification of Diseases, 9th Revision Clinical 
Modification (ICD-9-CM), until 2016, and the 10th Revision (ICD-10-CM), from 2017 
onwards. The ICD-9 and ICD-10 codes used to identify the different pathologies for this 










In 2014 a complementary codification approach was introduced in Portugal. All 
diagnoses were coded according to their presence or absence on admission. Pneumonia 
not “present on admission“ is, by definition, acquired in the hospital. Consequently, this 
codification allowed an easier and more accurate identification of HAP episodes. 
We retrospectively analyzed data from all adult patients discharged between Jan 1st 
2014 and Dec 31st 2017 with HAP, that is a pneumonia “not present on admission”. 
Patients under 18 years of age or with a hospital length of stay (LOS) of lessthan 48h 
were excluded. We collected administrative data, namely age and gender, the presence 
of chronic comorbidities, acute stroke, type of admission (either medical or for a 
surgical procedure) or ICU admission, along with outcomes, especially mortality, 
invasive mechanical ventilation and hospital LOS. 
We adopted a descriptive statistical analysis approach. Rates of HAP per 100 episodes 
of hospitalization and per 1000 hospital patient days (with 95% confidence intervals 
[CI]), according to age and gender, were computed for the whole population, for each 
year of the study and for the relevant subgroups. 
Continuous variables were expressed as mean ± square deviation and/or median 
[interquartile range] according to data distribution; the discrete variables were expressed 
as total number (percentage). 
The statistical significance analysis was performed using the Chi-square test (for 
discrete variables), Student’s T, Mann Whitney or Kolmogorov Smirnov tests (for 
continuous variables), according to data distribution. Odds Ratio (OR) with 95% CI 
were computed. 
All the calculations presented were obtained using the statistical software package R 










for statistical computing. R Foundation for Statistical Computing, Vienna, Austria) and 
the Microsoft Excel spreadsheet (Microsoft Corp., Redmond, WA, USA). 
This study was approved by the Central Administration of the Portuguese National 
Health System. As all individual patient information was protected and only aggregted 
data was available, the requirement for patient informed consent was waived. 
 
Results. 
Hospital-acquired pneumonia incidence 
A total of 3,026,233 hospital discharges were evaluated. We identified 28,632 episodes 
of HAP. The overall incidence was 0.95% and increased almost 5 times with age 
(Figure 1). The incidence of HAP per 1000 hospital-days was 1.13 (1.42 in men and 
0.85 in women). Male patients represented only 42.3% of all hospital admissions but 
accounted for 61.9% of HAP cases (figure 1). 
Overall, HAP was strongly associated with a prolonged LOS (mean 26.4 days) and with 
a very high mortality (33.6%), both significantly above the recorded values for general 
hospitalizations of ≥48h (mean LOS 8.4 days; mortality rate 6.7%; p<0.001). Mortality 
of patients with HAP also increased with age, attaining 40.1% in patients older than 85 
years. Even in patients <30 years, mortality was still 12.4%. 
The incidence of HAP was higher in patients admitted for a medical reason (1.1% vs. 
0.69% of surgical admissions, p<0.0001). As many as 5,383 (12.5%) of all patients 
ventilated in mainland Portugal during the study period had HAP, either before or as a 
complication of invasive mechanical ventilation, unveiling a significant burden of HAP 
in Intensive Care Medicine. Again, these patients had a high mortality rate (42%) and 










Comorbidities and hospital-acquired pneumonia 
Mortality was consistently higher in patients with HAP and chronic disease, e pecially 
chronic hepatic disease (44.2%). Moreover, mortality rate increased with the cumulative 
number of comorbidities, from 29.1% in patients without any diagnosed comorbidity to 
40.8% in patients with 2 or more (mortality OR for ≥ 1 comorbidity 1.48 95% CI 1.33-
1.65). 
Acute stroke was strongly associated with HAP (Figure 2). The overall stroke 
prevalence in HAP patients was 14.3% (with no significant gender difference), well 
above the reported 3.24% stroke prevalence for the general hospitalizations ≥ 48h. This 
association increased with age, roughly 1% per each 5 years, being 17.3% in patients
older than 85 years, whilst only 6% of all hospitalizations in the same age group had a 
diagnosis of stroke. Stroke patients (either ischaemic or haemorrhagic) who developed 




The incidence of HAP in mainland Portugal during a consecutive 4-year period, from 
2014 to 2017, was 0.95%, which corresponded to 1.13 episodes per 1000 hospital-days. 
Patients ≥65 years and male gender were significantly more prone to HAP, especially 
patients with an acute stroke. Hospital mortality was very high, at 33.6% overall, and 
increased sharply with age. Even patients without significant comorbidities had a 
mortality rate of roughly 30%, suggesting that attributable mortality may be su stantial. 
Hospital LOS was very long (26.4 days), roughly 3 times higher than that of the general 










An important limitation of retrospective studies addressing HAP is the relianc  on 
clinical diagnoses, especially as 2/3 of HAP may be acquired outside of the ICU [4,5], 
where classic signs of pneumonia may be missing in as many as half of the patients [6]. 
Automatic detection of HAP patients, based on oxygenation drop and antibiotic use, has 
recently been proposed [7] and may facilitate identification. 
As a consequence, the reported incidence of HAP seems to be mostly related to the 
definitions used to identify the cases and the included population. In a recently 
published European point prevalence study an overall incidence of 1.3% was noted [3] 
and a Portuguese HAP incidence of 2.7% was reported, much higher than we found in 
our study [3]. Hospital selection bias and a possible seasonal variation may help to 
explain these differences. 
A large study from the USA, including more than 6 million patients, reported a HAP 
incidence of 1.6%, corresponding to 3.63 per 1000 hospital-days [8], again higher than 
our rates. In this study HAP was defined as a discharge secondary diagnosis of 
pneumonia [8], whilst we only included patients with pneumonia considered to be “n t 
present on admission”. In contrast, a study done in 24 hospitals, using a HAP definition 
identical to ours [4] reported an incidence of 0.12-2.28 per 1000 hospital-days, very 
similar to ours. In the same study, LOS was also very long and 37.3% of HAP patients 
stayed in the hospital for more than 20 days [4]. 
The impact of HAP on outcome also seems to extend to the ICU. In a large cohort of 
ICU patients, the incidence of HAP was 5% in ventilated patients and 2% in non-
ventilated patients. The 30-day mortality was significantly increased in both groups 











In our study age was the most important predictor of HAP and more than 75% of HAP 
occurred in patients older than 65 years, unveiling a relationship between this 
pathology, senescence and frailty. Along with age, acute stroke may cause swallowing 
dysfunction and facilitate aspiration, both as a result of direct neurologic insult or as a 
consequence of oropharyngeal muscle weakness [10]. In our study, an interaction of age 
and acute stroke on the incidence of HAP, was disclosed (Figure 2). 
 
This study has some limitations: It relates only to Portuguese hospitals, relie  on a 
discharge diagnosis codification system, is retrospective, and limitations of the database 
do not allow segregation of ventilator associated HAP. Furthermore, the anonymized 
nature of the database did not allow us to perform discharge diagnosis audits to further 
validate the data. It also has several strengths. To our knowledge, it is the fir t HAP 
incidence study done at a national level, including both large and small community as 
well as teaching hospitals. Beside it includes data from 4 complete consecutive years, 
accounting for a potential seasonal variation. A large data base (including more than 3 
million hospital admissions) was evaluated, which strengthens our conclusions. 
 
In conclusion, HAP is common in hospital wards as well as in the ICU, and its 
incidence increased with age, male gender and stroke. It is associated with significant 
mortality, hospital LOS and health care resource utilization. The strong association with 
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Figure 1 – Incidence of hospital-acquired pneumonia 
The incidence of hospital-acquired pneumonia increased almost 5 times with age, 
mainly after 70 years. The curve trend was similar for both genders, although the 
incidence was twice as higher in males (OR 2.05, 95% CI 2.0-2.1, p<0.001). 
 
Figure 2 – association of acute stroke and hospital-acquired pneumonia 
A close relationship between age and the presence of stroke in patients with hospital-
acquired pneumonia was noted. The incidence of hospital-acquired pneumonia in all 
patients with stroke increased roughly 1.05% per evy 5 years of age (p<0.001 for 
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Supplementary File A  
 
Data requested from the National Health System Hospital database: 
1. Anonymized data from all adult hospital admissions (age >=18 years) with a 
hospitalization longer than 48h between 1st Jan 2014 and 31st Dec 2017 
2. Codes from: 2014 to 2016: ICD9-CM; 2017: ICD10-CM 
3. Number of all hospital admissions, mortality and mean length of hospital stay 
according to age and gender 
 
Study population 
All admissions with any discharge diagnosis of: 
- ICD9-CM: 480-486 (pneumonia) or 997.31 (ventilator associated pneumonia) 
that was “not present on admission” 
- ICD10-CM: J12-J18 (pneumonia), or J95.851 (ventilator associated pneumonia) 
that was “not present on admission” 
 
Data collected for each included patient: 
- Age, gender, hospital, admission and discharge day, outcome, day of first 
surgical procedure (if any), days in the ICU (if any), days on invasive mechanical 
ventilation, nosocomial infection, antibiotics; 
- 1st to 20th diagnoses with classification “present on admission – yes/no”; 
Procedures performed (1st to 20th); classification system (Homogeneous Diagnostic 
Group) 
 











A. ICD-9-CM  
 
1. Diabetes mellitus: 250.XX 
2. Chronic respiratory disease: 
- Obstructive Chronic Bronchitis: 
without exacerbation: 492.20 
with acute exacerbation: 492.21 
with acute bronchitis: 492.22  
- Emphysema: 492.8 
- Chronic respiratory failure chronic: 518.83 
- Acute on chronic respiratory failure: 518.84 
3. Chronic neurologic disease: 
- Late effects of cerebrovascular disease: 438 
- Dementias: 290.XX 
- Hereditary and Degenerative Diseases of the Central Nervous System (e.g., 
Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis): 330.XX a 
337.XX 
- Multiple sclerosis: 340 
4. Chronic renal disease: 
- Chronic Kidney Disease (Chronic uremia): 585.X 
5. Chronic liver disease: 
- Chronic liver disease and cirrhosis: 571.XX 
- Viral chronic hepatitis (B or C) with or without mention of hepatitis delta: 070.22, 
070.23, 070.32, 070.33, 070.44, 070.54 










- Systolic heart failure chronic: 428.22  
- Systolic heart failure acute on chronic: 428.23 
- Diastolic heart failure chronic: 428.32  
- Diastolic heart failure acute on chronic: 428.33 
- Combined systolic and diastolic heart failure chronic: 428.42 
- Combined systolic and diastolic heart failure acute on chronic: 428.43 
7. Acute stroke 
- Subarachnoid hemorrhage: 430 
- Intracerebral Hemorrhage: 431 
- Other and unspecified intracranial hemorrhage: 432.XX 
- Occlusion and stenosis of precerebral arteries: 433.X1 
- Occlusion  of cerebral arteries: 434.X1 
8.Invasive mechanical ventilation 
- IMV no specified length: 96.79 
- IMV <96 consecutive hours: 96.71 




1. Diabetes mellitus: E11.XX 
2. Chronic respiratory disease: 
- Emphysema: J43.X 
- Chronic obstructive pulmonary disease: J44.X 
- Chronic respiratory failure: J96.1X 










3. Chronic neurologic disease:  
- Late effects of cerebrovascular disease (sequelae): I69.XX  
- Dementias: F02.8X e F03.9X 
- Hereditary and Degenerative Diseases of the Central Nervous System (e.g., 
Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis): G10.XX-
G14.XX, G20.XX-G21.XX e G30.XX-G32.XX 
- Demyelinating diseases of the CNS (e.g., Multiple sclerosis): G35.XX-G37.XX 
4. Chronic kidney disease: 
- Chronic Kidney Disease: N18.X 
5. Chronic hepatic disease: 
- Chronic viral hepatitis: B18.X 
- Alcoholic fibrosis and sclerosis of liver: K70.2 
- Alcoholic cirrhosis of liver: K70.3X 
- Chronic hepatic failure (not elsewhere classified): K72.1X 
- Chronic hepatitis (not elsewhere classified): K73.X 
- Fibrosis and cirrhosis of liver: K74.XX 
6. Chronic heart disease with chronic heart failure or acute on chronic heart 
failure:  
- Systolic heart failure chronic: I50.22 
- Systolic heart failure acute on chronic: I50.23 
- Diastolic heart failure chronic: I50.32 
- Diastolic heart failure acute on chronic: I50.33 
- Combined systolic and diastolic heart failure chronic: I50.42 
- Combined systolic and diastolic heart failure acute on chronic: I50.43 










- Nontraumatic Subarachnoid Hemorrhage: I60.XX 
- Nontraumatic intracerebral hemorrhage: I61.XX 
- Other and unspecified non traumatic intracranial hemorrhage: I62.XX 
- Cerebral Infarction: I63.XX 
8. Invasive mechanical ventilation:  
- Respiratory Ventilation, less than 24 consecutive hours: 5A1935Z 
- Respiratory Ventilation, 24-96 consecutive hours: 5A1945Z 
- Respiratory Ventilation, greater than 96 consecutive hours: 5A1955Z 
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